




Optimal EPO Dosing Control in Hemodialysis

Coworkers: D. Fürtinger, F. Kappel, P. Kotanko, S. Rogg (Renal Research Institute New York & University of Graz)

Stefan Volkwein




RENAL
RESEARCH
INSTITUTE

University of Konstanz, Lecture Optimization III, October 27, 2022

Problem Formulation

Hormone EPO (Erythropoietin):


- produced in kidneys
- drives production of new red blood cells
- low EPO levels cause neocytolysis (active reduction of erythrocytes)



Chronic kidney disease:

- insufficient production and release of EPO
- chronic anemia (chronic lack of blood)
- exogenous EPO administration during hemodialysis treatments

Question: What are the „optimal“ EPO doses?



Optimal Control Problem

PDE-Constrained Optimization Problem:


$$\min J(\mathbf{y}, \mathbf{u}) \quad \text{subject to} \quad e(\mathbf{y}, \mathbf{u}) = 0 \quad \text{and} \quad \mathbf{u} \in \mathcal{U}_{\text{ad}}$$

Control input:

- administration time points (3 times per week): $t_1^*, t_2^*, t_3^*, \dots, t_m^* \in [t_o, t_f]$
- find EPO dose in $[0, E_{\text{max}}]$ for every $t_i^*, i = 1, \dots, m$
- vector $\mathbf{u} = (u_1, \dots, u_m) \in \mathbb{R}^m$, $\mathcal{U}_{\text{ad}} = \{ \mathbf{u} \in \mathbb{R}^m \mid 0 \leq u_i \leq 1 \text{ for } 1 \leq i \leq m \}$
- variable EPO doses: one component refers to one time
- constant EPO doses: one component refers to several times $\underbrace{t_1^*, t_2^*, t_3^*}_{u_1}, \underbrace{t_4^*, t_5^*, t_6^*}_{u_2}, \dots$

EPO concentration in blood:

- $E(t, \mathbf{u}) = E^{\text{ex}}(t, \mathbf{u}) + E^{\text{end}}$ with remaining endogenous E^{end}
- $E^{\text{ex}}(t, \mathbf{u}) = \frac{1}{c_{\text{tbv}}} \sum_{i=1}^m u_i \chi_i(t)$ with $\chi_i(t) = E_{\text{max}} e^{-\lambda(t-t_i^*)} \chi_{(t_i^*, \infty)}(t)$
- c_{tbv} total blood volume




State vector: $\mathbf{y} = (y_1, \dots, y_5)$ with population densities $y_i(t, x)$ and maturity $x \in [a_i, b_i]$

Model equations:

$$y_t(t, x) + \overbrace{v(E(t, u))}^{\text{maturation velocity}} y_x(t, x) = \left(\overbrace{\beta}^{\text{proliferation}} - \overbrace{\alpha(E(t, u), x)}^{\text{apoptosis}} \right) y(t, x)$$

$$y(t_0, x) = y_0(x)$$



Boundary conditions:

$$y_1(t, a_1) = S_0, \quad y_2(t, a_2) = y_1(t, b_1), \quad y_3(t, a_3) = y_2(t, b_2)$$

$$y_4(t, a_4) = \frac{y_3(t, b_3)}{v(E(t, u))}, \quad y_5(t, a_5) = v(E(t, u)) y_4(t, b_4)$$

Patient-depending functions:

$$\alpha_2(E) = \frac{\mu_1}{1 + \exp(\mu_2 E - \mu_3)}, \quad \alpha_5(E, x) = \alpha_5^0 + \chi_{[x_{\min}, x_{\max}]}(x) \cdot \tilde{\alpha}_5(E), \quad v(E) = \frac{\mu_4 - \mu_5}{1 + \exp(-\mu_6 E + \mu_7)} + \mu_5$$

Control input: $E(t, u) = \frac{1}{c_{\text{tbv}}} \sum_{i=1}^m u_i \chi_i(t) + E^{\text{end}}$ with $\chi_i(t) = E_{\text{max}} e^{-\lambda(t-t_i^*)} \chi_{(t_i^*, \infty)}(t)$




Desired total population: hemoglobin target range of 10-11 g/dl

Total erythrocytes population: $\int_{a_5}^{b_5} y_5(t, x) dx$

Cost functional:

$$J(\mathbf{y}, \mathbf{u}) = \frac{\sigma_{\Omega}}{2} \int_{t_0}^{t_f} \left| \int_{a_5}^{b_5} y_5(t, x) dx - y_d \right|^2 dt + \frac{\sigma_f}{2} \left| \int_{a_5}^{b_5} y_5(t_f, x) dx - y_d \right|^2 + \frac{1}{2} \sum_{i=1}^m \gamma_i |u_i|^2$$







with weights $\sigma_{\Omega}, \sigma_f, \gamma_i > 0$









Numerical optimization: projected Quasi-Newton, BFGS, Armijo

Discretization: Legendre polynomials

Numerical Experiments





References

Fuertinger/Kappel/Thijssen/Levin/Kotanko'13: A model of erythropoiesis in adults with sufficient iron availability, Math. Biol.

Mutsaers/Bachar/Batzel/Kappel/V.'11: Receding horizon controller for the baroreceptor loop in a model for the cardiovascular system, Card. Eng.

Rogg/Fürtinger/V./Kappel/Kotanko'18: Optimal EPO dosing in hemodialysis patients using a non-linear model predictive control approach, sub.